AstraZeneca (AZN) Receives “Overweight” Rating from Barclays

Barclays reiterated their overweight rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Monday morning.

Several other analysts have also commented on the stock. Berenberg Bank reissued a buy rating and set a GBX 6,200 ($80.76) target price on shares of AstraZeneca in a research note on Friday, June 8th. Shore Capital reissued a hold rating on shares of AstraZeneca in a research note on Friday, September 7th. Credit Suisse Group set a GBX 6,350 ($82.71) target price on shares of AstraZeneca and gave the company a buy rating in a research note on Thursday, August 30th. HSBC set a GBX 4,840 ($63.05) target price on shares of AstraZeneca and gave the company a sell rating in a research note on Wednesday, August 15th. Finally, Deutsche Bank reissued a buy rating and set a GBX 6,000 ($78.16) target price (up from GBX 5,700 ($74.25)) on shares of AstraZeneca in a research note on Friday, July 13th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the stock. The company currently has an average rating of Hold and an average target price of GBX 5,689.45 ($74.11).

AZN stock opened at GBX 5,843 ($76.11) on Monday. AstraZeneca has a 12 month low of GBX 4,260 ($55.49) and a 12 month high of GBX 5,520 ($71.90).

The company also recently declared a dividend, which was paid on Monday, September 10th. Investors of record on Thursday, August 9th were given a GBX 68.40 ($0.89) dividend. The ex-dividend date of this dividend was Thursday, August 9th. This represents a dividend yield of 1.19%.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: How are the companies in the S&P 500 selected?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply